From: <u>Kulinski, Joseph</u>
To: <u>Michelle Olsen</u>

Cc: Agnihothram, Sudhakar; Resnick, Josephine

Subject: STN 125752: Information Request #33 / CBER Labeling Revisions

Date: Friday, December 10, 2021 5:35:00 PM

Attachments: <u>image001.pnq</u>

125752 annotated draft labeling text - CBER Comments 12.10.2021.docx 125752 annotated draft labeling text - CBER Comments 12.10.2021.pdf

Dear Dr. Olsen:

Our review of your August 24, 2021 submission (STN 125752/2) is ongoing. Please review the attached annotated revised package insert and accept all revisions in the word document as you feel appropriate. For changes not accepted and/or for any further revisions, please retain the tracking information and provide the rationale for changes not accepted and for additional edits. Please provide both an tracked changes and clean copy of the revised package insert in your response. We also have the following additional comment:

- 1. Please refer to the following labels:
 - Multiple-dose 5.5 mL (10 dose) vial carton label, NDC 80777-100-99
 - Multiple-Dose 5.5 mL vial container label, NDC 80777-100-11
 - Multiple-Dose 7.5 mL (10 Doses) vial carton label, NDC 80777-100-98
 - Multiple-Dose 7.5 mL vial container label, NDC 80777-100-15

Please change the wording "No Preservative" to "Contains No Presentative" on each of these labels.

Please confirm your receipt of this request, and provide your responses as an amendment to STN 125752 at your earliest convenience but no later than December 14, 2021.

Thank you, Joe

Joseph Kulinski, PhD Biologist / Primary Reviewer

CBER/OVRR/DVRPA

U.S. Food and Drug Administration

Phone: (301) 796-2640 joseph.kulinski@fda.hhs.gov













THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.